BridgeBio Pharma, Inc. (BBIO)
NASDAQ
81.50
-1.44 (-1.74%)
Closed
Aug 21, 2026
Day's Range
81.3683.37
52 wk Range
46.8193.42
Financial Statements - BBIO - BridgeBio Pharma, Inc.
Revenue
502.07M▲ 126.3%
Net Income
-732.93M▼ 34.9%Net Margin -146.0%
EBITDA
-506.32M▲ 12.9%
Free Cash Flow
-455.50M▲ 14.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 502.07M | 221.90M | 9.30M | 77.64M | 69.71M | 8.24M |
| Cost of Goods | 20.96M | 3.87M | 2.44M | 3.43M | 3.11M | 0 |
| Gross Profit | 481.11M | 218.02M | 6.85M | 74.21M | 66.60M | 8.24M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -502.06M | -577.36M | -599.44M | -468.43M | -576.63M | -474.48M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -72.05M | 117.21M | 9.44M | 56.68M | 35.82M | 1.63M |
| Pre Tax Income | -732.50M | -542.19M | -653.25M | -484.65M | -586.45M | -505.48M |
| Income Tax | 435K | 1.15M | - | - | - | - |
| Net Income | -732.93M | -543.34M | -653.25M | -484.65M | -586.45M | -505.48M |
| EPS Basic | -3.78 | -2.88 | -3.95 | -3.26 | -3.9 | -3.8 |
| EPS Diluted | -3.78 | -2.88 | -3.95 | -3.26 | -3.9 | -3.8 |
| Basic Shares Outstanding | 191.52M | 186.07M | 162.79M | 147.47M | 144.35M | 117.99M |
| Diluted Shares Outstanding | 191.52M | 186.07M | 162.79M | 147.47M | 144.35M | 117.99M |
| Ebit | -554.26M | -442.90M | -571.96M | -404.21M | -539.67M | -468.83M |
| Ebitda | -506.32M | -581.09M | -574.64M | -339.17M | -569.65M | -469.01M |
| Net Income Continuous Operations | -732.93M | -543.34M | -653.25M | -484.65M | -586.45M | -505.48M |
| Minority Interests | 8M | 7.58M | 10.04M | 3.46M | 23.91M | 56.76M |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
